10.14.15
Vetter has opened a new business entity in Tokyo, Japan. Hiroaki Suzuki will serve as business development manager for Vetter Pharma International Japan K.K., and will lead business activities in Japan, reporting to director of key account management Asia Pacific, Chervee Ho based in Singapore.
Japan is home to several global pharmaceutical companies with promising injectable pipelines. The new office will support customer relations and aid in the development of new business within Japan, while strengthening the global position of Vetter, particularly in selected Asia Pacific markets. Vetter supports early product development through to launch and commercial supply.
“Our presence in Japan will help to increase awareness of Vetter’s services in this growing healthcare market by presenting our expertise and market position onsite,” said managing director Peter Soelkner. “Following the creation of our Asia Pacific hub in Singapore last year, the new office is a further development, establishing a dedicated presence in the most important single market of the region. This activity affords us the opportunity to strengthen personal contacts with national audiences.”
“Vetter’s decision to expand their presence in the Asia Pacific region and to open their first office in Japan is a strong message of their commitment to service the needs of this important market,” said Dr. Hitoshi Kuboniwa, senior vice president and general manager of Pharmaceutical Technology Division at Chugai Pharmaceutical Co., Ltd. “As a trusted partner, we appreciate that step, wishing Vetter as a company in general, and Ms. Ho and Mr. Suzuki in particular, a promising start for their onsite activities in Japan.”
Japan is home to several global pharmaceutical companies with promising injectable pipelines. The new office will support customer relations and aid in the development of new business within Japan, while strengthening the global position of Vetter, particularly in selected Asia Pacific markets. Vetter supports early product development through to launch and commercial supply.
“Our presence in Japan will help to increase awareness of Vetter’s services in this growing healthcare market by presenting our expertise and market position onsite,” said managing director Peter Soelkner. “Following the creation of our Asia Pacific hub in Singapore last year, the new office is a further development, establishing a dedicated presence in the most important single market of the region. This activity affords us the opportunity to strengthen personal contacts with national audiences.”
“Vetter’s decision to expand their presence in the Asia Pacific region and to open their first office in Japan is a strong message of their commitment to service the needs of this important market,” said Dr. Hitoshi Kuboniwa, senior vice president and general manager of Pharmaceutical Technology Division at Chugai Pharmaceutical Co., Ltd. “As a trusted partner, we appreciate that step, wishing Vetter as a company in general, and Ms. Ho and Mr. Suzuki in particular, a promising start for their onsite activities in Japan.”